Catecholamines participate in the induction of ornithine decarboxylase gene expression in normal and hyperplastic mouse kidney.
In the quinazoline antifolate (CB 3717)-induced hyperplastic kidney model, a remarkable increase of ornithine decarboxylase (ODC) activity was paralleled by a smaller, but highly significant augmentation of the ODC transcript level. Catecholamine depletion, evoked by reserpine, strongly impaired antifolate-induced ODC expression; the enzyme activity was almost completely abolished while the mRNA level decreased by 60%. Moreover, under conditions of a depleted catecholamine pool, kidney enlargement was significantly reduced confirming our earlier reports on the indispensability of ODC induction for renal hyperplasia (M. Manteuffel-Cymborowska et al. , Biochim. Biophys. Acta, 1182 (1993) 133-141[1]). In normal mouse kidney catecholamines appeared to be inducers of ODC expression. Use of selective agonists of catecholamine receptors demonstrated the importance of dopamine D2 receptors, and to a lower extent beta adrenoreceptors, in the catecholamine mediation of induction of ODC activity and of ODC mRNA levels. These increases were not abolished by an antiandrogen, casodex, suggesting that catecholamine control of ODC expression is an androgen receptor-independent process. The results obtained point to the critical role of renal catecholamines; these biogenic amines are not only involved in the regulation of ODC expression in normal kidney but are also required for the induction of ODC in hyperplastic kidney evoked by antifolate and, as shown recently (M. Manteuffel-Cymborowska et al., Biochim. Biophys. Acta, 1356 (1997) 292-298[2]), in testosterone-induced hypertrophic kidney.
Dudkowska
M
M
Nencki Institute of Experimental Biology, 3 Pasteur Street, 02-093, Warsaw, Poland.
Manteuffel-Cymborowska
M
M
Chmurzyńska
W
W
Grzelakowska-Sztabert
B
B
D000818:Animals; D002395:Catecholamines / Q000172:deficiency*; D005260:Female; D005492:Folic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D005493:Folic Acid Antagonists / Q000494:pharmacology; D015870:Gene Expression; D006965:Hyperplasia / Q000139:chemically induced / Q000201:enzymology; D007668:Kidney / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology; D051379:Mice; D009929:Organ Size / Q000187:drug effects; D009955:Ornithine Decarboxylase / Q000096:biosynthesis* / Q000235:genetics; D011799:Quinazolines / Q000494:pharmacology; D012333:RNA, Messenger / Q000032:analysis; D017983:Receptors, Catecholamine / Q000819:agonists / Q000032:analysis; D012110:Reserpine / Q000494:pharmacology
D002395:Catecholamines; D005493:Folic Acid Antagonists; D011799:Quinazolines; D012333:RNA, Messenger; D017983:Receptors, Catecholamine; C031662:CB 3717; D012110:Reserpine; D005492:Folic Acid; D009955:Ornithine Decarboxylase